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Summary
The peripheral nervous system is a frequent target of toxic agents. The accurate identification 
of the sites of neurotoxic action through the morphological characterization of reliable in vivo 
models or in vitro systems can give fundamental clues when investigating the pathogenesis 
and interpreting the clinical features of drug-induced neuropathy.
The morphological approach has been used to investigate almost all the anticancer drugs able 
to induce chemotherapy-induced peripheral neurotoxicity, i.e. platinum drugs, antitubulins and 
proteasome inhibitors. No models have ever been described for thalidomide.
This review demonstrates that any pathogenetic study on chemotherapy-induced peripheral 
neurotoxicity must be based on solid morphological observations obtained in reliable animal 
and in vitro models. This is particularly true in this setting, since the availability of tissues of 
human origin is extremely limited. In fact, peripheral (generally sural) nerve biopsies are never 
required for diagnostic purposes in chemotherapy-treated cancer patients, and their use for a 
purely scientific aim, although potentially very informative, is not ethical. Moreover, several 
neurotoxic drugs target the dorsal root ganglia neurons, and it is very difficult to obtain high-
quality specimens even from early autopsies. 
It is, therefore, our opinion that an extensive morphological assessment of the in vitro and in 
vivo effect of any potentially neurotoxic antineoplastic drugs, as well as of neuroprotectant 
agents, should be taken into consideration right from the earliest stages of their development.
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Introduction
The role of careful morphological examinations in modern experimental neuro-
toxicology is frequently challenged in view of the availability of new, powerful and 
sophisticated techniques. However, several examples could be offered in support of 
the still fundamental importance of this “old” assessment method, when carefully 
used, as a mandatory step in the overall process. 
As far as the peripheral nervous system (PNS) is concerned, clear evidence is pro-
vided by the important role of morphology in the understanding of chemotherapy-
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induced peripheral neurotoxicity (CIPN) which will be discussed in this paper. The 
PNS is a frequent target of the neurotoxicity of several compounds and toxic agents. 
The accurate identification of their sites of neurotoxic action, as well as the careful 
study of the morphological features induced in the nervous system in in vivo models 
or in well-characterized in vitro systems, can allow reliable clues to be obtained when 
investigating the pathogenesis and interpreting the clinical features of drug-induced 
neuropathy.
Among the various environmental, industrial and pharmacological agents able 
to damage the PNS, the neurotoxic effect of several antineoplastic drugs represents a 
major clinical problem, given their widespread use and the potential severity of their 
toxicity that may be a dose-limiting side effect. 
Neurotoxicity studies in this field clearly demonstrate the importance of a mor-
phological assessment in this kind of investigation. In fact, while the clinical features 
of CIPN may suggest the possible target of toxicity, only morphological studies can 
actually demonstrate if a structure is really involved in the pathological process and 
to what extent. For instance, the clinical evidence that in CIPN distal sensory symp-
toms/signs predominate over motor impairment would seem to indicate that the pri-
mary sensory neurons located in the dorsal root ganglia (DRG) are the most frequent 
targets of drugs’ neurotoxic action, but only a morphological examination of DRG in 
experimental models and in a few human specimens could confirm this hypothesis.
The specific morphological features of neuronal damage induced at different 
levels by platinum compounds, taxanes, vinca alkaloids and bortezomib, together 
with their importance in properly addressing subsequent focused research, will be 
described. No models have ever been described for thalidomide.
The clinical features of CIPN
The involvement of the PNS in CIPN can be clinically evidenced by the occur-
rence of sensory impairment with or without neuropathic pain, weakness and/or 
autonomic impairment. The different anticancer drugs known to induce CIPN may 
determine one or more of these clinical signs/symptoms, even if sensory impairment 
is generally more frequent and severe.
The most extensively studied neurotoxic antineoplastic drugs that have entered 
into clinical practice include platinum drugs (cisplatin, oxaliplatin, carboplatin), 
antitubulins (vincristine, taxanes, epothilones), bortezomib and thalidomide. 
Although some aspects are similar among the various treatments, every class of 
drugs has its characteristic toxicity profile and so clinical symptoms and signs, as 
they generally appear during the treatment with the main antineoplastic drugs, will 
be described in this chapter.
Sensory impairment
As previously mentioned, sensory symptoms and signs are often isolated or large-
ly prominent over motor impairment in most CIPN patients (Cavaletti et al., 2007a, 
Quasthoff and Hartung, 2002). Loss of sensitivity or paresthesias, often painful, can 
occur early in the course of chemotherapy and may persist even after treatment with-
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drawal. Sensory symptoms are usually worst in the lower limbs and they have a 
distal-to-proximal gradient. Sensory signs include decreased touch, pin, thermal and 
vibration perception. Reflexes are often lost, especially at the ankles, as an early sign 
(Cavaletti et al., 2004).
Typically, platinum compounds produce a pattern of sensory loss consistent with 
primary ganglionopathy and proprioceptive loss may result in ataxia leading to 
severe functional impairment (Cavaletti, 2008, Cavaletti et al., 2007a). Besides their 
toxicity to the DRG and peripheral nerves, platinum compounds can also be respon-
sible for deafness, being toxic to the cochlea hairy cells (Schweitzer, 1993). All the var-
ious classes of antitubulins (vinca alkaloids, taxanes, epothilones) induce sensorimo-
tor neuropathy, but distal sensory impairment with reduced pain/thermal perception 
and touch hypoesthesia with non-painful paresthesia are generally more severe than 
motor impairment (Cavaletti and Marmiroli, 2010, Cavaletti and Marmiroli, 2004). By 
contrast, pure sensory impairment in pain, thermal and touch perception are the most 
common clinical features experienced by multiple myeloma patients treated with 
bortezomib and/or thalidomide (Cavaletti and Marmiroli, 2010).
Lhermitte’s phenomenon (indicating the involvement of the centripetal branch of 
the sensory pathway within the spinal cord) has occasionally been reported after cis-
platin and oxaliplatin and also after taxane (paclitaxel or docetaxel) administration 
(Taieb et al., 2002, van den Bent et al., 1998, Inbar et al., 1992). 
Neuropathic pain
Neuropathic pain is a prominent and important side effect for many treated sub-
jects. Patients often report this symptom during the administration of the platinum 
drugs, paclitaxel and vincristine (Siau et al., 2006), and in the case of bortezomib its 
severity may be so great as to be dose-limiting particularly in the treatment of multi-
ple myeloma (Cavaletti and Nobile-Orazio, 2007). 
Motor impairment
In most cases the motor symptoms and signs are minor. Weakness is generally 
clinically evident in the distal muscle groups; it may be  detected only on examina-
tion or it may be more severe with foot drop and distal weakness. Muscular weak-
ness due to motor neuropathy is more frequently observed after the administration of 
antitubulin drugs (taxanes, epothilones or vinca alkaloids). 
Muscle cramps are a common, underestimated symptom particularly in patients 
undergoing oxaliplatin administration and myalgias are frequent in taxane-treated 
patients. 
Autonomic impairment
This  may result in a wide spectrum of symptoms, including orthostatic hypoten-
sion, constipation and dysfunction of sexual organs and micturition. In general, auto-
nomic symptoms are relatively infrequent in CIPN, but they can be dose-limiting in 
vincristine-treated subjects (Swain and Arezzo, 2008).
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Incidence of CIPN
The real incidence of CIPN has not been clearly established due to marked dif-
ferences in the assessment methods and to the difficulty in demonstrating the pres-
ence of pre-existing neuropathy in patients undergoing second-line treatments after 
a potentially neurotoxic first-line chemotherapy. Moreover, several neurotoxic anti-
neoplastic drugs are used together in polychemotherapy schedules for the treat-
ment of selected kinds of solid or hematological cancers, with a subsequent possible 
increase in the incidence and severity of CIPN and/or the appearance of combined 
neurotoxicity.
The observed incidence of CIPN in patients receiving a platinum drug + taxanes 
chemotherapy may approach 70% (Argyriou et al., 2007, Argyriou et al., 2005), with 
severe CIPN in at least 10% of patients. A similarly high incidence of CIPN may also 
be detected in bortezomib-treated patients, particularly when the drug is combined 
with thalidomide (Chaudhry et al., 2008, Lanzani et al., 2008, Argyriou et al., 2008).
The role of morphological studies in the understanding of CIPN pathophysiology
As already observed, based on the clinical features of CIPN, it is very likely 
that the primary sensory neurons located in the DRG are the most  probable tar-
get of drugs neurotoxic action. This hypothesis is supported by several well estab-
lished observation regarding the anatomy of DRG neurons. Firstly, primary sen-
sory neurons lie outside the blood-brain barrier (BBB) and are supplied by cap-
illaries with fenestrated walls that allow the free passage of molecules between 
the bloodstream and the extracellular fluid. Moreover, the axons of these cells are 
among the longest of the entire nervous system and, therefore, are more suscepti-
ble to any agent that interferes with the energy metabolism or the structural basis 
of axonal transport (e.g. drugs interfering with the normal cytoskeleton struc-
ture or damaging mitochondrial activity thus impairing axonal transport due to 
energy failure). Finally, neurons rely on programmed cell death pathways that are 
particularly sensitive to DNA damage, a primary target of several antineoplastic 
chemotherapeutic agents. 
In spite of these interesting hypotheses, knowledge regarding the mechanism of 
the neurotoxic action of chemotherapeutic drugs is still largely incomplete. 
In an attempt to increase what is known about CIPN pathogenesis, several pre-
clinical models have been established and used to perform extended morphological 
and morphometric evaluations. These studies  have made it possible to collect much 
of the most relevant information regarding CIPN pathophysiology and to generate 
hypotheses for subsequent focused investigations. 
Although in vivo animal models have obvious advantages in terms of similarities 
with clinical conditions, they are expensive, time-consuming and the interpretation of 
their results is often difficult at a molecular level due to the great number of variables 
to be analysed. 
Therefore, reliable in vitro models based on the morphological examination of 
DRG or isolated sensory neurons cultures have also been developed. 
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In vivo studies
Several animal models of CIPN have been developed in recent years and have 
been used to examine DRG as well as peripheral nerve changes induced by treat-
ment and to compare the results with functional assessments, e.g. neurophysiological 
or behavioral investigations. The sciatic nerve can be effectively used to assess the 
involvement of large, rather proximal, nerve fibers while caudal or digital nerves can 
be used to study the most distal parts of the nerve, where the earliest signs of toxicity 
generally ensue (Canta et al., 2010). Very recently, skin biopsies have also been used 
with the aim of investigating the most distal parts of sensory nerves and of applying 
a method already available in clinical practice for studying distal polyneuropathies 
(Bianchi et al., 2006, Lauria et al., 2005).
The molecular changes induced by antineoplastic drugs at different sites (i.e. 
DRG, peripheral nerves) have also been studied at the pathological level with immu-
nolocalization studies (Barajon et al., 1996). 
In vitro studies
CIPN has been investigated in vitro using various cellular approaches. Several data 
have been obtained by employing tumoral cell lines such as SH-SY5Y human neuro-
blastoma and rat PC12 pheochromocytoma cells. Both cell lines have the disadvantage 
of not being “true” neurons but they can be differentiated in culture into “neuronal-
like” cells. SH-SY5Y cells are human cells, they express neuronal genes and may be 
considered as being neuroblasts at a different stage of differentiation. In addition, SH-
SY5Y cells differentiate and develop neurites after retinoic acid (RA) treatment without 
the addition of neurotrophic factors. PC12 cells are rat cells and their differentiation is 
dependent on Nerve Growth Factor (NGF); this is a limitation in the use of the PC12 
cell line in the study of growth factors’ neuroprotection. In both cellular models CIPN 
has been studied by measuring neurite length. Furthermore, both cellular models  are 
suitable for studying the molecular mechanisms implicated in CIPN (Villa et al., 2005, 
Rigolio et al., 2005, Nicolini et al., 2003, Nicolini et al., 2001). 
Embryonic (E15) or adult rat DRG explants are also suitable models for studying 
CIPN. In fact, DRG are the main target of several antineoplastic drugs and from DRG 
it is possible to establish both organotypic cultures and primary cultures (neurons or 
satellite cells).  E15 or adult rat DRG harbor post mitotic sensory neurons that are 
able to elongate neurites after NGF addition. Moreover, rat DRG primary cultures 
allow the effect of antineoplastic drugs on myelination to be studied (Podratz et al., 
2004). Neurotoxicity in DRG organotypic cultures can be evaluated by measuring the 
length of the longest neurite of each DRG, by analysing the intricacy of the neurite 
tree and the number of branches (Radio and Mundy, 2008) or by quantifying the den-
sity of neurite arborisation (Shah et al., 2004) (Fig. 1). 
Neurotoxicity of the different agents
Platinum drugs
As already mentioned, the selective vulnerability of sensory neurons is thought to 
be secondary to the higher concentration of neurotoxic drugs able to reach the DRG. 
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In agreement with this suggestion, platinum or paclitaxel concentrations measured in 
DRG are very close to those achievable in tumor tissue,  while much lower concen-
trations can be detected in the BBB-protected central nervous system (Thompson et 
al., 1984, Gregg et al., 1992, Cavaletti et al., 1990). Using antibodies able to recognize 
platinum-DNA adducts, it has subsequently been demonstrated that platinum binds 
avidly to DRG neuronal DNA during treatment with both cisplatin and oxaliplatin 
(McDonald et al., 2005, Ta et al., 2006, Meijer et al., 1999). 
Figure 1 – Phase contrast light micrographs showing neurite outgrowth in dorsal root ganglia explants after 
24 h (top) and 48 h (bottom) NGF exposure.
81Chemotherapy-induced peripheral neurotoxicity
The first reliable and extended pathological report of cisplatin-induced DRG dam-
age appeared in 1986 (Tomiwa et al., 1986) and it described the effect of the acute 
administration of cisplatin. In that model cisplatin treatment produced a segregation 
of the dense fibrillar from the granular component in DRG neurons nucleoli. A dis-
organization of ribosomes was also found in more severely intoxicated animals, with 
shrinkage of the Nissl substance and an increase in neurofilaments. Hypertrophy of 
the satellite cells with an increase in the perineuronal intercellular spaces, often associ-
ated with irregular, scalloped nuclear and cell outlines, suggested that neuron shrink-
age had occurred (Tomiwa et al., 1986). A few years later, similar features were dem-
onstrated in our laboratory using chronic, long-lasting schedules of cisplatin adminis-
tration developed to mimic more closely the long-term administration of the drug in 
clinical practice (Pisano et al., 2003, Cavaletti et al., 2001, Tredici et al., 1998, Cavaletti 
et al., 2002b, Cavaletti et al., 2002a, Cavaletti et al., 1992, Cavaletti et al., 1998, Cavaletti 
et al., 1990, Cavaletti et al., 1994, Bianchi et al., 2006). Also in our animals an irregu-
lar nuclear profile was frequently observed, although the nucleoplasm was of normal 
density. However, the most striking changes occurred in the nucleolus. Although mult-
inucleolated neurons and nucleolar eccentricity were present also in healthy rats, their 
incidence was markedly increased after platinum administration. Moreover, several 
nucleoli underwent a segregation of their components (Fig. 2) and the damage could 
be so severe that focal clearing of the nucleolus occurred in some neurons. The sat-
ellite cells were much less involved than neurons although changes were evident in 
the nucleus, where a thinning of the chromatin layer was frequently observed at the 
ultrastructural examination. The morphometric determination of the somatic, nuclear 
and nucleolar size performed on DRG neurons demonstrated a significant and dose-
dependent cellular atrophy after chronic platinum administration in comparison with 
healthy age-matched rats. Formal morphometric assessment of the number of neu-
rons present in the lumbar DRG did not evidence any neuronal loss due to treatment, 
which is in agreement with the results obtained in the DRG with the TUNEL method 
that did not show apoptotic nuclei in the neurons (Tredici et al., 1999).
In contrast with the evident morphological and morphometric changes demon-
strated in the DRG, the pathological changes in the peripheral nerves of platinum-
intoxicated rats are very mild (Cavaletti et al., 1992). In the sciatic nerve a significant 
decrease in the mean diameter of myelinated fibers was evident, mainly affecting the 
fibers over 10 µm in diameter, and it was associated with a shift to the left of the fiber 
size distribution histogram indicating an increase in the density of smaller fibers. In 
agreement with the absence of neuronal loss in the DRG, the total number of myeli-
nated fibers (which was directly measured in the saphenous nerve) was unchanged 
after cisplatin treatment, as were the overall density and the estimated number of 
myelinated fibers in the sciatic nerve (Tredici et al., 1999). 
The same morphological changes observed in cisplatin-treated animals were subse-
quently described also in carboplatin- or oxaliplatin-treated rats (Cavaletti et al., 1998, 
Cavaletti et al., 2002a, Cavaletti et al., 2001) and correlated with evident neurophysi-
ological changes in nerve conduction velocity in the tail nerve (Tredici et al., 1994). 
Cisplatin and oxaliplatin toxicity in vitro has been evaluated in SH-SY5Y human 
neuroblastoma cells in our laboratory (Cece et al., 1995; Nicolini et al., 1998; Donzelli 
et al., 2004). Morphological studies demonstrated that both cisplatin and oxaliplatin 
induced apoptotic death in SH-SY5Y undifferentiated cells. In fact cisplatin- or oxali-
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platin-treated SH-SY5Y cells appeared positive to TUNEL staining (Fig. 3) and in the 
same cells caspases 3 and 7 were activated. Moreover, platinum-treated SH-SY5Y cells 
detached from the substrate and presented shrunken cell bodies, chromatin conden-
sation, nuclear blebbing and cytoplasmic degeneration.
Cisplatin cytotoxic effect on RA-differentiated SH-SY5Y cells is much lower com-
pared  to the effect on undifferentiated cells. By contrast, it is important to underline 
the neurotoxic effect of the drug on RA-differentiated SH-SY5Y cells. RA-differentiated 
cells treated with cisplatin (for 24 hours) show a significant reduction in mean neur-
ite length directly correlated with the drug concentration. Cisplatin determines also a 
Figure 2 – High power photomicrographs at the electron microscope showing the nucleolar segregation 
induced by chronic cisplatin administration in a rat dorsal root ganglia neuron (bottom) in comparison with 
an untreated rat (top).
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reduction in the percentage of differentiated SH-SY5Y cells, namely those with a neu-
rite longer than 50 µm, i.e mean + 2SD of the longest neurite previously determined 
in non-differentiated cultures (Fig. 4).
Cisplatin and oxaliplatin toxicity in vitro has also been evaluated in E15 rat DRG 
neurons and apoptosis has been demonstrated (Fig. 5) (Scuteri et al., 2009). This 
apparent discrepancy with most of the in vivo results, which frequently failed to evi-
dence apoptosis in DRG neurons, is probably due to the general toxicity of platinum 
drugs in rat and mice that prevents the high doses being reached that are required to 
achieve these results using long-term treatments. However, apoptosis in DRG neu-
rons has been demonstrated also in vivo using short-term, high-dose schedules (Fis-
cher et al., 2001).
Antitubulin drugs
The family of neurotoxic antitubulin drugs includes three main classes of com-
pounds: vinca alkaloids, taxanes and epothilones. All these drugs interfere with 
microtubule assembly and mitotic spindle formation, although through different 
mechanisms. The vinca alkaloids act by inhibiting the assembly and promoting the 
disassembly of microtubules (Himes et al., 1976). By contrast, the taxanes and the 
epothilones hyperstabilize microtubule subunit cross-linking. The antitubulin activi-
ties of the latter drugs has two well-established effects: a) the increased stability of 
microtubules decreases the ability of the cell to dynamically reorganize the cytoskel-
eton and b) the increased cross-linking results in the formation of crystalline arrays 
of microtubule subunits in the cell body or axon (Apfel, 2000). However, alternative 
toxic mechanisms have been suggested by recent animal studies demonstrating mito-
chondrial damage in the distal parts of peripheral nerves after paclitaxel administra-
tion (Xiao et al., 2009, Jin et al., 2008). 
Figure 3 – TUNEL staining of SH-SY5Y undifferentiated neuroblastoma cells after cisplatin exposure. 
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Among the vinca alkaloids vincristine is the drug that has been most extensively 
examined. Data generated by in vivo animal studies support localized axonal toxicity 
as a cause of distal axonal degeneration due to vincristine and are consistent with the 
largely predominant axonal damage which has been described in human sural nerve 
biopsy pathological examinations (McLeod and Penny, 1969, Postma et al., 1993, 
Authier et al., 2003, Authier et al., 1999, Higuera and Luo, 2004, Sahenk et al., 1987). In 
these models, axonopathy with Wallerian-like degeneration of myelinated and unmy-
elinated fibers has been clearly evidenced, and the pathological changes are correlat-
Figure 4 – Phase contrast undifferentiated (top) and retinoic acid (RA)-treated SH-SY5Y neuroblastoma cells.
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ed with neuropathic pain assessed with behavioral tests (Ghirardi et al., 2005). Even 
if autonomic involvement may be dose-limiting in vincristine treatment, as already 
observed, at present no reliable model of vincristine-induced autonomic impairment 
is available. 
While several models of paclitaxel neurotoxicity have been reported in past years, 
docetaxel models of chronic administration in vivo have been reported only very 
recently by our group (Persohn et al., 2005). The earliest studies performed in the 
1980s reported that the direct intraneural injection of paclitaxel into the sciatic nerve 
induced axonal reactions and degeneration that are causally related to the slow pro-
gressive accumulation of microtubules and other axoplasmic constituents. This culmi-
Figure 5 – Phase contrast photomicrograph showing dorsal root ganglia neuron primary cultures after NGF 
differentiation followed by 24 h oxaliplatin treatment (top). DNA fragmentation in neuron nuclei is demon-
strated by Hochest 33342 staining (bottom).
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nated in the appearance of giant axonal spheroids and profiles similar to the retrac-
tion bulbs of Wallerian degeneration. Microtubule anomalies were also visualized in 
the distal portion of affected fibers and in regenerating sprouts. Schwann cells dis-
played microtubule abnormalities only at the site of the lesion where excessive micro-
tubule polymerization caused the displacement of ribosomes from rough endoplas-
mic reticulum (Roytta and Raine, 1986). However, this model was based on a modal-
ity of administration that was able to overcome any anatomical protective barrier of 
the peripheral nerves.
Figure 6 – Toluidine blue-stained light photomicrographs obtained from a transverse sections of sciatic 
nerve in an untreated (top) and a paclitaxel-treated (bottom) rat.
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We, therefore, characterized at the histological and ultrastructural level the effect 
of intraperitoneal and intravenous administrations of paclitaxel (Cavaletti et al., 
2000, Cavaletti et al., 1997, Cavaletti et al., 1995) and compared the effect of docetaxel 
treatment using different schedules (Persohn et al., 2005) of chronic treatment. The 
examination at the light microscope of nerve sections from paclitaxel- or docetaxel-
treated animals evidenced that most of the myelinated fibers were of normal aspect, 
although some fibers with axonal degeneration, including collapse and fragmentation 
Figure 7 – Light micrographs of skin biopsies stained with PGP 9.5 to evidence the dermal and intra-epider-
mal (arrows) nerve fibers. A dramatic reduction in the intra-epidermal innervation is induced by docetaxel 
administration (bottom) if compared with the normal pattern (top). 
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of myelin sheaths, could be observed (Fig. 6). The morphometric evaluation showed 
a significant decrease in g-ratio (i.e. the ratio between axonal diameter and the entire 
fiber diameter) in paclitaxel-treated animals, confirming the occurrence of axonopa-
thy. The mean fiber diameter was significantly decreased in paclitaxel-treated animals 
and, accordingly, there was a significant increase in the percentage of myelinated 
fibers with a diameter smaller than 5.5 µm when compared with the controls (Per-
sohn et al., 2005). Electron microscopic examination of the sciatic nerve from treated 
animals confirmed primary axonal degeneration. Moreover, Schwann cells with con-
densed chromatin and “nucleolus-like” formations or enlarged intracytoplasmic orga-
nelles were observed. Occasionally, an accumulation of microtubules was observed 
within the axons of animals treated with both drugs. Dose-dependent changes in 
tail nerve conduction velocity were demonstrated with paclitaxel and docetexel (Per-
sohn et al., 2005). The use of injury markers such as activating transcription factor-3 
Figure 8 – Phase contrast photomicrographs showing the effect of paclitaxel (right) after 24 h (top) and 48 h 
(bottom) exposure in NGF fully differentiated dorsal root ganglia explants in comparison with controls (left).
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(ATF3) in DRG neurons after taxanes treatment made it possible to confirm that pacli-
taxel is toxic also at this cellular level (Flatters and Bennett, 2006). Accordingly, a high 
concentration of paclitaxel was demonstrated in the DRG (Cavaletti et al., 2000). In 
a different rodent model of paclitaxel neuropathy axonal damage was also demon-
strated in dorsal (sensory) but not in ventral (motor) spinal roots (Wang et al., 2004). 
When we assessed the intraepidermal nerve fiber density in skin biopsies, a diag-
nostic procedure already used in humans (Lauria et al., 2005), to evaluate the most 
distal changes occurring in taxane-treated animals, a decrease in fiber density was 
demonstrated and the correlation with the neurophysiological assessment was highly 
significant (Fig. 7). 
The first animal model of epothilone B peripheral neuropathy  has recently been 
established in our laboratory (Chiorazzi et al., 2009). The pathological examination 
Figure 9 – Light (top) and electron microscope (bottom) findings in dorsal root ganglia specimens obtained 
from untreated (left) and bortezomib-treated (right) rats. Evident vacuolation of satellite cells is shown in the 
treated animals, while neurons are of normal appearance.
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at the light and electron microscope of the peripheral nerves and DRG neurons gave 
results very similar to those obtained in taxanes models.
In in vitro studies 1 mM paclitaxel induces apoptosis in the SH-SY5Y human neu-
roblastoma cell line (Nicolini et al., 2001; Nicolini et al., 2003). The treatment causes 
chromatin condensation, DNA laddering and phosphatidylserine translocation. These 
morphological data indicating ongoing apoptosis are in agreement with molecu-
lar results that demonstrate Bcl-2 inactivation and caspase 7 activation. By contrast, 
1 mM paclitaxel induces necrotic death in E15 rat DRG neurons, while no apoptot-
ic features have been demonstrated (Scuteri et al., 2006). In this case morphological 
and ultrastructural studies have demonstrated that neurons  die through a necrotic 
process. Paclitaxel shows a dose and time-related effect on neurite length on NGF-
differentiating E15 rat DRG, while it does not affect neurite length but only the mor-
phology and the number of the processes of fully differentiated E15 rat DRG (Fig. 8). 
Similar results have been obtained by Theiss and Meller (2000) in primary cultures of 
sensitive neurons from 11-day-old chick embryos. 
Paclitaxel neurotoxicity has also been demonstrated in NGF differentiated PC12 
cells (Nuydens et al., 2000; Pisano et al., 2003). Paclitaxel in this in vitro model induces 
a reduction in neurite outgrowth and in the number of neurite-bearing cells.
According to in vivo results, in vitro data indicate a reduction in neurite length 
in E15 rat DRG treated also with epothilone B 0.1 and 0.5 nM. Epothilone B induces 
a significant reduction in neurite length at 24 hours that is reversed at 48 hours after 
the treatment, while concentrations higher than 5 nM determine neurite length reduc-
tions both at 24 and 48 hours of exposure.
Bortezomib
Bortezomib is a polycyclic derivative of boronic acid that inhibits the mammalian 
26S proteasome. The proteasome degrades the intracellular inhibitor of NFkB (IkB) 
and so bortezomib increases the level of the inhibitor and decreases the activity of 
NFkB. The drug also binds to the tumor necrosis factor receptor type 1 (TNFR1). 
Through these mechanisms, bortezomib appears to sensitize cancer cell to inducers 
of apoptosis and to reduce the rate of cell division (Tobinai, 2007, O’Connor, 2005, 
Schwartz and Davidson, 2004). The mechanism underlying its peripheral neurotoxic-
ity is unknown, but enhanced tubulin polymeration has been observed in cancer cells 
and neurons (Poruchynsky et al., 2008).
At the current time only a few rat models of bortezomib-induced peripheral neu-
rotoxicity have been reported (Carozzi et al., 2010, Meregalli et al., 2009, Cavaletti et 
al., 2007b, Bruna et al., 2010) and various schedules have been compared. At the light 
and electron microscope, sciatic nerve examination demonstrated the earliest changes 
mostly in the Schwann cells and myelin, but neuropathy due to axonal degeneration 
(the most typical effect of bortezomib administration in clinical use) was observed 
only after prolonged drug administration. At the ultrastructural level the pathologi-
cal changes in Schwann cells were generally represented by mild vacuolation but, in 
the most severe cases of Schwann cell damage, cytoplasmatic involvement was more 
evident and the vacuoles were larger. In these cases, some of the vacuoles were found 
to be damaged mitochondria, while others were due to locally enlarged endoplas-
mic reticulum. In these in vivo models bortezomib-treated rats showed  a significant 
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increase in the g-ratio, indicating an overall reduced thickness of the myelin sheath 
which was in agreement with the pathological observations (Meregalli et al., 2009).
Also in the DRG, satellite cells were generally more severely damaged than neu-
rons, with marked intracytoplasmatic vacuolization (Fig. 9). At the ultrastructural 
examination some of these vacuoles were clearly represented by damaged mitochon-
dria, while the largest structures were due to enlarged endoplasmic reticulum. Only 
rarely did DRG neurons display pathological features at the light microscope: in these 
cases the cytoplasm showed  a dark appearance with clear vacuoles occurring inside. 
These observations which point to mitochondrial and endoplasmic reticulum damage 
as a major effect of chronic bortezomib treatment in the sciatic nerve Schwann cells 
and DRG are intriguing, particularly in view of some of the mechanisms of action 
which have recently been suggested for bortezomib in cancer cells. In fact, several 
studies have evidenced that bortezomib is particularly effective in killing myeloma 
cells because it is able to induce the activation of the mitochondrial-based (“intrin-
sic”) apoptotic pathway. In most cases, no nuclear changes were observed in satellite 
cells or in neurons, although very rarely mild segregation of the granular and fibrillar 
components of the nucleolus was observed in neurons. The morphometric examina-
tion did not evidence any significant difference in DRG neuron somatic, nuclear or 
nucleolar size. 
In vitro studies on E15 rat DRG demonstrated a very steep dose response curve, 
suggesting a limited “therapeutic window” range between non neurotoxic concentra-
tions and highly cytotoxic ones.
Conclusions
Based on the clinical features and on the symptoms and signs most frequently 
reported by patients suffering from CIPN, several morphological studies have been 
performed in animal models of CIPN and in in vitro studies in order to investigate 
the neurotoxicity of different antineoplastic drugs.
Animal models have been established for the majority of the most important anti-
cancer drugs and their main pathological changes in the PNS have been described in 
this report, together with in vitro observations.
These studies are very important in this particular setting, since the availability 
of tissues of human origin is extremely limited. In fact, peripheral (generally sural) 
nerve biopsies are no longer required for diagnostic purposes in CIPN patients, and 
their use for a purely scientific aim, although potentially very informative, is not eth-
ical. Moreover, as suggested by the clinical findings and confirmed by the preclini-
cal studies, several neurotoxic drugs target the DRG neurons, and it is very difficult 
to obtain high-quality specimens even from early autopsies. In any case, even when 
these types of post-mortem analysis have been carried out, it is necessary to bear in 
mind that most of the cancer patients are treated with polychemotherapy schedules, 
thus making the interpretation of the results very uncertain.
When the morphological data were compared with neurophysiological and behav-
ioral studies, the results were confirmed and, overall, they have undoubtedly been 
very useful for understanding some of the mechanisms of action of the neurotoxic 
antineoplastic drugs. Thus, it appears absolutely clear that, despite the implementa-
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tion of sophisticated methods of investigation, the basis for any pathogenetic study 
on the toxic effect of anticancer drugs must still rely on solid morphological observa-
tions obtained in reliable animal and in vitro models.
It is, therefore, our opinion that, given the amount and the relevance of the infor-
mation available, a focused morphological assessment of the in vitro and in vivo 
effects of any potentially neurotoxic antineoplastic drug, as well as of putative neuro-
protective agents, should be included in the preclinical phase of any new drug right 
from the earliest stages of its development - an approach the importance of which 
tends to be frequently underestimated.
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